Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company is a sponsor of the Renewable Fuels Association’s (RFA) 18th Annual National Ethanol Conference. The conference is taking place February 5 — 7, 2013 at the Wynn Las Vegas in Las Vegas, Nevada.
The RFA’s National Ethanol Conference is recognized as one of the premier forums for the ethanol industry to come together and work to address the current market situation and issues facing the industry. Verenium is pleased to support such an important event and to be part of the discussion on how products like Verenium’s Fuelzyme® alpha-amylase enzyme, can help ethanol producers recognize multiple sources of savings such as reduced chemical usage and dose reduction, and improve plant profitability in tough market conditions.
To learn more about Fuelzyme® alpha-amylase and Verenium’s other grain processing enzyme solutions, look for product information on the sponsor table at the upcoming 18th Annual RFA National Ethanol Conference or contact Verenium Customer Relations at firstname.lastname@example.org and 1.800.523.2990.
For more information on the RFA’s National Ethanol Conference visit http://www.nationalethanolconference.com/.
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium’s tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.
Forward Looking Statements for Verenium
Statements in this press release that are not strictly historical are “forward-looking” and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium’s ability to commercialize its products, enhance its manufacturing capabilities, capture near-term and longer-term growth and prospects, and reach profitability. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium’s strategic focus, technologies, products and product candidates and product pipeline (including Verenium’s ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights, protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium’s dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium’s technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium’s filings with the Securities and Exchange Commission, including, but not limited to, Verenium’s annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q . These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.
For more information on: Verenium